WALTHAM, Mass.--(BUSINESS WIRE)-- NeurAxon, Inc. today announced several scientific presentations by officers and advisors to the Company at the International Symposium on Nitric Oxide and Other Gaseous Neurotransmitters, May 27 – 28, 2010 in Toronto, Ontario. NeurAxon is focused on the discovery and development of next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.
The following presentations related to the Company and its technology will take place on Thursday, May 27, 2010 at the MaRS Center Auditorium in Toronto, Ontario:
About NeurAxon, Inc.
NeurAxon, Inc. (www.neuraxon.com) discovers and develops next-generation pain therapeutics focused on its first-in-class selective inhibitors of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.
MacDougall Biomedical Communications
Chris Erdman, 508-647-0209 x14
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS: Health Biotechnology